Journal of Artificial Organs

, Volume 16, Issue 4, pp 498–500

Arrhythmogenic right ventricular cardiomyopathy: use of a left ventricular assist device as a bridge to transplantation?

  • Hani N. Mufti
  • Miroslaw Rajda
  • Jean-Francois Legare
Case Report Artificial Heart (Clinical)


The principal characteristic of arrhythmogenic right ventricular cardiomyopathy (ARVC) is the tendency for ventricular arrhythmia and sudden death to occur without overt ventricular dysfunction. Current recommendations for management of patients with ARVC include insertion of an automated implantable cardioverter–defibrillator (AICD) to prevent sudden cardiac death. However, despite the use of AICD and/or anti-arrhythmic drugs some patients suffer recurrent ventricular arrhythmias unresponsive to optimum medical management. We present two cases of ARVC with refractory recurrent ventricular arrhythmias that were successfully managed by left ventricular assist device (LVAD) implantation, as a bridge to transplant (BTT). These two cases are unconventional examples of use of LVAD, given the predominant right ventricular pathology of ARVC and the arrhythmogenic nature of their presentation. The novelty of these cases should be taken in the context of increasing pressure to standardize indications for use of mechanical circulatory support.


Ventricular assist device Arrhythmia Heart transplant Heart failure 


  1. 1.
    McNally E, MacLeod H, Dellefave L. Arrhythmogenic right ventricular dysplasia/cardiomyopathy, autosomal dominant. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle WA: University of Washington, Seattle 1993.Google Scholar
  2. 2.
    Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005;112:3823–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Boilson BA, Raichlin E, Park SJ, Kushwaha SS. Device therapy and cardiac transplantation for end-stage heart failure. Curr Probl Cardiol. 2010;35:8–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Ambardekar AV, Buttrick PM. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart fail. 2011;4:224–33.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Birks EJ, George RS, Firouzi A, Wright G, Bahrami T, Yacoub MH, et al. Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. J Thorac Cardiovasc Surg. 2012;144:190–6.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Artificial Organs 2013

Authors and Affiliations

  • Hani N. Mufti
    • 1
    • 3
  • Miroslaw Rajda
    • 2
  • Jean-Francois Legare
    • 1
  1. 1.Division of Cardiac Surgery, Department of Surgery, Queen Elizabeth II Health Sciences CentreDalhousie UniversityHalifaxCanada
  2. 2.Division of Cardiology, Department of Medicine, Queen Elizabeth II Health Sciences CentreDalhousie UniversityHalifaxCanada
  3. 3.Department of SurgeryKing Abdulaziz Medical City, National Guard Health AffairsJeddahSaudi Arabia

Personalised recommendations